Celltrion secures new public tenders for two biosimilars in Peru
According to Korea Biomedical Review (KBR), the company’s flagship autoimmune disease treatment, called ‘Remsima’, has secured a substantial tender from the Peruvian Workers’ Insurance System (EsSalud). This tender